Zusammenfassung
Das Peritoneum ist ein Mesothel, eine einfache Schicht eines squamösen Epithels mesenchymatösen Ursprunges. Die Gesamtfläche des Peritoneums beträgt in etwa so viel wie die Körperoberfläche selbst. Das Peritoneum ist eine bidirektionelle, semipermeable Membran, die das Volumen der Flüssigkeit in der peritonealen Höhle kontrolliert, die eine wichtige Rolle in der antibakteriellen Abwehr spielt und die Migration der Abwehrzellen von der mikrovaskulären Seite aus ermöglicht. Diese Membran kann durch eine Großzahl von Erkrankungen betroffen sein. Sowohl benigne als auch maligne Erkrankungen können eine chirurgische Behandlung erfordern. Der Autor hat dem Thema der Peritonektomie und der hyperthermen Chemotherapie (HIPEC) eine besondere Beachtung geschenkt.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Bakrin N, Cotte E, Golfier F, Gilly FN, Freyer G, Helm W, Glehen O, Bereder JM (2012) Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol 19: 4052–4058
Baratti D, Pennacchioli E, Kusamura S et al. (2010) Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? Ann Surg Oncol 17: 3220–3228
Beaujard A, Glehen O, Caillot JL et al. (2000) International chemohyperthermia with Mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 88: 2513–2519
Canda AE, Sokmen S, Terzi C et al. (2013) Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 20: 1082–1087
Chan DL, Morris DL, Rao A et al. (2012) Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res 4: 413–422
Cavaliere F, De Simone M, Virzì S et al. (2011) Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol 37: 148–154
Chua TC, Yan TD, Saxena A et al. (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 249: 900–907
Chua TC, Morris DL, Saxena A et al. (2011) Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol 18(6): 1560–1567
Chua TC, Moran BJ, Sugarbaker PH et al. (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30: 2449–2456
Duhr CD, Kenn W, Kickuth R et al. (2011) Optimizing of preoperative computed tomography for diagnosis in patients with peritoneal carcinomatosis. World J Surg Oncol 9: 171
Elias D, Blot F, El Otmany A, Antoun S et al. (2001) Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92: 71–76
Elias D, Lefevre JH, Chevalier J et al. (2009) Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 27: 681–685
Elias D, Honoré C, Dumont F et al. (2011) Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 254: 289–293
Esquivel JE, Sugarbaker PH (1998) Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to. Cancer Ther 1: 321–325
Esquivel J, Vidal-Jove J, Steves MA et al. (1993) Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 113: 631–636
Gill RS, Al-Adra DP, Nagendran J et al. (2011) Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 104: 692–698
Glehen O, Osinsky D, Cotte E et al. (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10: 863–869
Glehen O, Cotte E, Schreiber V et al. (2004) Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 91: 747–754
Glehen O, Gilly FN, Arvieux C et al. (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17: 2370–2377
Glockzin G, Schlitt HJ, Piso P (2009) Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 7: 5
González Bayón L, Sugarbaker PH et al. (2003) Initiation of a program in peritoneal surface malignancy. Surg Oncol Clin N Am 12: 741–753
Graziosi L, Cantarella F, Mingrone E et al. (2013) Preliminary results of prophylactic HIPEC in patients with locally advanced gastric cancer. Ann Ital Chir 84: 551–556
Harmon RL, Sugarbaker PH (2005) Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2: 3
Hayes-Jordan A, Green H, Ludwig J et al. (2012) Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: early experience and phase 1 results. Pediatr Blood Cancer 59: 395–397
Heiss MM, Murawa P, Koralewski P et al. (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127: 2209–2221
Jaquet P, Sugarbaker P (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15: 49–58
Jacquet P, Stephens AD, Averbach AM et al. (1996) Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 77: 2622–2629
Konate A, Poupon J, Villa A et al. (2011) Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure. J Surg Oncol 103: 6–9
Kusamura S, Baratti D, Hutanu I et al. (2012) The importance of the learning curve and surveillance of surgical performance in peritoneal surface malignancy programs. Surg Oncol Clin N Am 21: 559–576
Mohamed F, Moran BJ (2009) Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer 15: 196–199
Moradi III BN, Esquivel J (2009) Learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 100: 293–296
Moran BJ, Mukherjee A, Sexton R (2006) Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 93: 100–104
Nougaret S, Addley HC, Colombo PE et al. (2012) Ovarian carcinomatosis: how the radiologist can help plan the surgical approach. Radiographics 32: 1775–1800
Pelz JO, Stojadinovic A, Nissan A et al. (2009) Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 99: 9–15
Pelz JO, Chua TC, Esquivel J et al. (2010) Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer 10: 689
Pfannenberg C, Königsrainer I, Aschoff P et al. (2009) (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 16: 1295–1303
Pilati P, Mocellin S, Rossi CR et al. (2003) Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 10: 508–513
Sammartino P, Sibio S, Biacchi D et al. (2012) Prevention of peritoneal metastases from colon cancer in high-risk patients: Preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Pract 2012: 141585
Schmid K, Boettcher MI, Pelz JO et al. (2006) Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with mitomycin C. Eur J Surg Oncol. 32: 1222–1225
Stephens AD, Alderman R, Chang D et al. (1999) Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6: 790–796
Sugarbaker PH (1998) Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 14: 254–261
Sugarbaker PH (2005) A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol 32: S68–S73
Sugarbaker PH (2012) Early intervention for treatment and prevention of colorectal carcinomatosis: a plan for individualized care. Surg Oncol Clin N Am 21: 689–703
Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221: 124–132
Verwaal VJ, Ruth S van, de Bree E, Sloothen GW van, Tinteren H van, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol: official journal of the American Society of Clinical Oncology 21: 3737–3743, doi:10.1200/JCO.2003.04.187
Verwaal VJ, van Tinteren H, Ruth SV et al. (2004) Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 85: 61–67
Votanopoulos K, Ihemelandu C, Shen P et al. (2013) A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 179: e133–e139
Yan TD, Black D, Savady R et al. (2007a) A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 14: 484–492
Yan TD, Links M, Fransi S et al. (2007b) Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy – a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 14: 2270–2280
Yan TD, Deraco M, Baratti D et al. (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27: 6237–6242
Yonemura Y, Tsukiyama G, Miyata R et al. (2010) Indication of peritonectomy for peritoneal dissemination. Gan To Kagaku Ryoho 37: 2306–2311
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Pelz, J. (2017). Peritoneum. In: Billmann, F., Keck, T. (eds) Facharztwissen Viszeral- und Allgemeinchirurgie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48308-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-662-48308-4_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-48307-7
Online ISBN: 978-3-662-48308-4
eBook Packages: Medicine (German Language)